Immunotherapy of advanced renal cell carcinoma: Current and future therapies

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) historically had limited treatment options.
• Cytokine therapies like interferon-alfa and interleukin-2 are used less frequently now.
• The recent approval of nivolumab, an immune checkpoint inhibitor, revitalized immunotherapy for mRCC.

Purpose of the Study:

• To review the mechanism of action, clinical outcomes, and toxicity of approved and investigational immunotherapies for mRCC.
• To highlight the evolving landscape of mRCC treatment driven by immunotherapy.

Main Methods:

• Review of clinical data for approved immunotherapies.
• Analysis of investigational immunotherapies currently under study for mRCC.
• Assessment of treatment efficacy, safety profiles, and mechanisms of action.

Main Results:

• Immune checkpoint inhibitors, such as nivolumab, represent a significant advancement in mRCC therapy.
• Numerous novel immunotherapeutic agents are under investigation, alone or in combination.
• These new treatments offer encouraging prospects for managing mRCC.

Conclusions:

• The understanding of tumor-immune system interactions is crucial for developing effective mRCC immunotherapies.
• Novel immunotherapies, including immune checkpoint inhibitors, are transforming mRCC treatment paradigms.
• Future therapeutic strategies for mRCC will likely involve combinations of these promising agents.